CFDE Data Portal | Search PDE7B-AS1

	Label	Description
	PDE7B-AS1 Gene (Entity type)	ENSG00000237596 - PDE7B antisense RNA 1
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE233679 12 V 0 NICOTINAMIDE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE238213 dopamine 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978 GSE180930 cisplatin 6 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE165960 MEK inhibition 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

PDE7B-AS1

ENSG00000237596 - PDE7B antisense RNA 1

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE233679 12 V 0 NICOTINAMIDE HUMAN UP

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 5 human up

A Gene Set from LINCS

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP

A Gene Set from LINCS

GSE238213 dopamine 2 v 0 human up

A Gene Set from LINCS

GSE238018 MXRA8 knockout MDA-MB-231 3 v 5 human up

A Gene Set from LINCS

GSE119978 GSE180930 cisplatin 6 v 7 human dn

A Gene Set from LINCS

GSE165960 MEK inhibition 0 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.